2. The concept of amyloid positive will be extensively discussed, and the attendees should be able to characterize the advantages and disadvantages of both dichotomized and continuous variable approaches to amyloid PET analyses with respect to specific purposes or intended uses of the outcome.
3. Attendees will have the opportunity to evaluate amyloid PET data in specific clinical and clinical research contexts, including review of typical findings in Alzheimer’s disease dementia, mild cognitive impairment due to Alzheimer’s disease, and in clinically normal individuals. These phenomena will also be related to familial forms of the disease and to non-AD processes such as fronto-temporal lobar degeneration and dementia with Lewy Bodies.
4. Particular attention will be given to the assessment of longitudinal amyloid PET data as it relates to methods of analysis and comparison to other domains of data, including structural and functional brain imaging data, and clinical and cognitive outcomes.
For the forthcoming conference, we will be continuing with debates as well as adhering to the format of the previous conferences which are designed to provide an in-depth progress report on new antiepileptic drugs in various stages of development, as well as to present new findings on second-generation treatments.
Conference-Service.com offers, as part of its business activities, a directory of upcoming scientific and technical meetings. The calendar is published for the convenience of conference participants and we strive to support conference organisers who need to publish their upcoming events. Although great care is being taken to ensure the correctness of all entries, we cannot accept any liability that may arise from the presence, absence or incorrectness of any particular information on this website. Always check with the meeting organiser before making arrangements to participate in an event!